Chronic kidney disease–mineral and bone disorder as multidimensional bone–vascular risk framework: from biochemical control to risk-and context-guided care

Chronic kidney disease-mineral and bone disorder (CKD-MBD) is a systemic complication that spans early CKD, dialysis and kidney transplantation. It is better understood not as an isolated disturbance of calcium and phosphate metabolism but as a multidimensional, dynamic syndrome in which mineral-endocrine dysregulation, skeletal remodeling, skeletal fragility and structural consequences, and vascular calcification interact to shape patient outcomes. This narrative review argues that management should move beyond the control of biochemical targets toward phenotype-informed, evidence-graded and outcome-oriented care organized around the bone–vascular axis. We first examine why surrogate-based management has under performed and then propose a working multidimensional framework based on four interrelated domains mineral and endocrine status, bone turnover and mineralization, skeletal fragility and structural consequences, vascular calcification and cardiovascular risk, and clinical modifiers and treatment context. We also grade the evidence behind the principal mechanisms and interventions, from phosphate retention, the FGF23-Klotho axis, vitamin D-PTH dysregulation, Wnt/β-catenin signaling and calciprotein particles to inflammation, gut dysbiosis and uremic toxins, distinguishing mechanistic plausibility from observational association, surrogate-endpoint trials and hard-endpoint benefit. We then match diagnostic tools, including bone turnover markers, DXA, HR-pQCT, 18F-NaF PET/CT, vascular calcification scoring, calcification propensity testing and bone biopsy, to the clinical decisions they are meant to inform, and reframe treatment of hyperphosphatemia, secondary hyperparathyroidism, CKD-associated osteoporosis and vascular calcification by multidimensional framework. The recurring theme is that biochemical improvement is not itself benefit: the field needs stratified, testable strategies anchored in fracture, cardiovascular events, hospitalization, mortality, quality of life and physical function.

Authors

Institutions

Publication Details

Journal
Frontiers in Endocrinology
Published
2026-10-29
DOI
https://doi.org/10.3389/fendo.2026.1954515
Primary Topic
Parathyroid Disorders and Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Chronic kidney disease–mineral and bone disorder as multidimensional bone–vascular risk framework: from biochemical control to risk-and context-guided care

Kang Yang, Tao Li, Guanting Chen, Linqi Zhang et al.
Frontiers in Endocrinology
Parathyroid Disorders and Treatments
article

Chronic kidney disease–mineral and bone disorder as multidimensional bone–vascular risk framework: from biochemical control to risk-and context-guided care

Kang Yang, Tao Li, Guanting Chen, Linqi Zhang, Yaoxian Wang
article en

Abstract

Chronic kidney disease-mineral and bone disorder (CKD-MBD) is a systemic complication that spans early CKD, dialysis and kidney transplantation. It is better understood not as an isolated disturbance of calcium and phosphate metabolism but as a multidimensional, dynamic syndrome in which mineral-endocrine dysregulation, skeletal remodeling, skeletal fragility and structural consequences, and vascular calcification interact to shape patient outcomes. This narrative review argues that management should move beyond the control of biochemical targets toward phenotype-informed, evidence-graded and outcome-oriented care organized around the bone–vascular axis. We first examine why surrogate-based management has under performed and then propose a working multidimensional framework based on four interrelated domains mineral and endocrine status, bone turnover and mineralization, skeletal fragility and structural consequences, vascular calcification and cardiovascular risk, and clinical modifiers and treatment context. We also grade the evidence behind the principal mechanisms and interventions, from phosphate retention, the FGF23-Klotho axis, vitamin D-PTH dysregulation, Wnt/β-catenin signaling and calciprotein particles to inflammation, gut dysbiosis and uremic toxins, distinguishing mechanistic plausibility from observational association, surrogate-endpoint trials and hard-endpoint benefit. We then match diagnostic tools, including bone turnover markers, DXA, HR-pQCT, 18F-NaF PET/CT, vascular calcification scoring, calcification propensity testing and bone biopsy, to the clinical decisions they are meant to inform, and reframe treatment of hyperphosphatemia, secondary hyperparathyroidism, CKD-associated osteoporosis and vascular calcification by multidimensional framework. The recurring theme is that biochemical improvement is not itself benefit: the field needs stratified, testable strategies anchored in fracture, cardiovascular events, hospitalization, mortality, quality of life and physical function.

Frontiers in EndocrinologyVol. 17
Henan University of Traditional Chinese Medicine (CN), First Affiliated Hospital of Henan University of Traditional Chinese Medicine (CN), First Affiliated Hospital of Henan University (CN)
National Natural Science Foundation of China, Henan Provincial Science and Technology Research Project
Good health and well-being
Openalex Percentile: Top 12%
Parathyroid Disorders and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon